Incretin-based therapy for heart failure with reduced ejection fraction: why we need a trial
26.7 26.5 26.4 27.1 26.7 27.5 27.0 27.1 27.6 Median BMI Potential concerns about the safety of incretin-based therapies are unproven and based on incomplete and inconsistent data from underpowered studies Full height of bar shows the proportion of patients with a BMI 30 kg/m 2 and yellow inset those with a BMI 35 kg/m 2 .*Mean BMI
Authors
- John J.V. McMurray (ORCID: https://orcid.org/0000-0002-6317-3975)
- Jawad H. Butt (ORCID: https://orcid.org/0000-0002-7380-4144)
- Scott David Solomon (ORCID: https://orcid.org/0000-0003-3698-9597)
Institutions
- Brigham and Women's Hospital (US)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- British Heart Foundation (GB)
Publication Details
- Journal
- European Heart Journal
- Published
- 2025-08-14
- DOI
- https://doi.org/10.1093/eurheartj/ehaf635
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29